BRIEF-Aimmune Therapeutics announces data supporting safety, tolerability profile of AR101
June 13, 2016 at 11:44 AM EDT
* Data from AR101 for peanut allergy showed safety and tolerability profile improved with continued treatment
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|